Key result
Hyperbaric oxygen therapy preconditioning prior to doxorubicin treatment increased antioxidant response but did not prevent doxorubicin-induced cardiorespiratory dysfunction.
Why the study?
Cardiorespiratory dysfunction from doxorubicin chemotherapy impairs patient outcomes, and whether hyperbaric oxygen preconditioning can enhance muscle antioxidant capacity and preserve cardiorespiratory function remained unknown.
Does hyperbaric oxygen preconditioning prevent doxorubicin-induced cardiorespiratory dysfunction in adult female Sprague Dawley rats?
Does hyperbaric oxygen preconditioning prevent doxorubicin-induced cardiorespiratory dysfunction in adult female Sprague Dawley rats?
Hyperbaric oxygen preconditioning increases antioxidant expression but is not sufficient to prevent doxorubicin-induced cardiorespiratory dysfunction in a rat model.
May attenuate DOX-induced cardiorespiratory dysfunction in preclinical models; leaves open clinical utility in chemotherapy patients.
Cardiorespiratory dysfunction resulting from doxorubicin (DOX) chemotherapy treatment is a debilitating condition affecting cancer patient outcomes and quality of life. DOX treatment promotes cardiac and respiratory muscle pathology due to enhanced reactive oxygen species (ROS) production, mitochondrial dysfunction and impaired muscle contractility. In contrast, hyperbaric oxygen (HBO) therapy is considered a controlled oxidative stress that can evoke a substantial and sustained increase in muscle antioxidant expression. This HBO-induced increase in antioxidant capacity has the potential to improve cardiac and respiratory (i.e., diaphragm) muscle redox balance, preserving mitochondrial function and preventing muscle dysfunction. Therefore, we determined whether HBO therapy prior to DOX treatment is sufficient to enhance muscle antioxidant expression and preserve muscle redox balance and cardiorespiratory muscle function. To test this, adult female Sprague Dawley rats received HBO therapy (2 or 3 atmospheres absolute (ATA), 100% O2, 1 h/day) for 5 consecutive days prior to acute DOX treatment (20 mg/kg i.p.). Our data demonstrate that 3 ATA HBO elicits a greater antioxidant response compared to 2 ATA HBO. However, these effects did not correspond with beneficial adaptations to cardiac systolic and diastolic function or diaphragm muscle force production in DOX treated rats. These findings suggest that modulating muscle antioxidant expression with HBO therapy is not sufficient to prevent DOX-induced cardiorespiratory dysfunction.
No takes yet. Share an insight, caveat, or question.
Doerr et al. (2022) studied Doxorubicin cardiorespiratory toxicity. Hyperbaric oxygen (HBO) therapy vs. 2 ATA HBO / No HBO was evaluated on Cardiac systolic and diastolic function and diaphragm muscle force production. Hyperbaric oxygen therapy preconditioning prior to doxorubicin treatment increased antioxidant response but did not prevent doxorubicin-induced cardiorespiratory dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: